Please provide your email address to receive an email when new articles are posted on . Patients with refractory Crohn’s disease previously exposed to ustekinumab benefited from risankizumab. Findings ...

RALEIGH, N.C., Aug. 18, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology ...

On August 18, 2025, Accord BioPharma, Inc. (“Accord BioPharma”) announced the commercial launch of IMULDOSA® (ustekinumab-srlf), a biosimilar to STELARA® (ustekinumab) in the United States. IMULDOSA® ...

Company's immunology franchise demonstrates strong market momentum with preferred status under one of the largest pharmacy benefit managers in the nation IMULDOSA, a biosimilar to STELARA® ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...

Ustekinumab is effective for CD, especially in patients with previous treatment failures, showing significant clinical response and remission rates in trials. The safety profile of ustekinumab is ...

DNA methylation biomarkers predicted response to vedolizumab and ustekinumab in patients with Crohn's disease. Prediction models outperformed existing tools for vedolizumab and ustekinumab, especially ...

PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), and Alvotech (ALVO) today announced that ...